Neoadjuvant peptide receptor radionuclide therapy for aninoperable neuroendocrine pancreatic tumor
Authors:
- Daniel KaemmererDKDaniel Kaemmerer
- Vikas PrasadVPVikas Prasad
- Wolfgang DaffnerWDWolfgang Daffner
- Dieter HörschDHDieter Hörsch
- Günter KlöppelGKGünter Klöppel
- Merten HommannMHMerten Hommann
- Richard P BaumRBRichard P Baum
Open Access
- 1 January 2009
- journal article
- case report
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 15 (46) , 5867-5870
Abstract
Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumorKeywords
This publication has 17 references indexed in Scilit:
- Nonfunctioning neuroendocrine pancreatic tumors: our experience and managementJournal of Hepato-Biliary-Pancreatic Surgery, 2009
- Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177 Lu DOTA-TATE and 177 Lu DOTA-NOCCancer Biotherapy and Radiopharmaceuticals, 2007
- TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading systemVirchows Archiv, 2006
- Resection of Pancreatic Neuroendocrine TumorsArchives of Surgery, 2006
- Visualisation of a somatostatin receptor-expressing tumour with 67Ga-DOTATOC SPECTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Tumoren des endokrinen PankreasDer Pathologe, 2005
- Surgery of Resectable Nonfunctioning Neuroendocrine Pancreatic TumorsWorld Journal of Surgery, 2004
- Aggressive surgery for metastatic liver neuroendocrine tumorsSurgery, 2003
- DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusionEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003